Could Serum Level of Prostate-specific Antigen after High Energy Transurethral Microwave Thermotherapy for Benign Prostatic Hyperplasia Predict and Represent Efficacy of the Treatment?.
- Author:
Kee Keun SONG
1
;
Kyung Keun SEO
;
Sae Chul KIM
Author Information
1. Department of Urology, College of Medicine, Chung-Ang University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Benign prostatic hyperplasia;
High energy transurethral microwave thermotherapy;
Prediction;
Efficacy;
Prostate-specific antigen
- MeSH:
Humans;
Male;
Microwaves;
Prostate;
Prostate-Specific Antigen*;
Prostatic Hyperplasia*;
Transurethral Resection of Prostate*;
Urinary Bladder Neck Obstruction
- From:Korean Journal of Urology
1999;40(7):858-863
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate serum level of prostate-specific antigen(PSA) after high energy transurethral microwave thermotherapy(HE-TUMT) for benign prostatic hyperplasia(BPH) could predict and represent efficacy of the treatment. MATERIALS AND METHODS: In patients with BPH who underwent HE-TUMT using Prostatron with Prostasoft 2.5(EDAP-Technomed, France), serum levels of PSA at 7 days(n=37), 3 months(n=40), and 6 months(n=26) after the treatment were compared with Madsen and international prostate symptom score(MSS and IPSS), maximal and average uroflow rate(MFR and AFR), and postvoiding residual urine(PVR) of 6 months after the treatment. RESULTS: The subjective(MSS and IPSS) and objective(PFR, AFR, and PVR) parameters were significantly(p<0.05) improved at 6 months after the treatment. The postoperative serum level of PSA showed a 643.2% increase(0.5-2870%) at 7 days(more than 500% increase in 18 men and less than 500% in 19), a 34.9% increase(79% decrease?303% increase) at 3 months, and a 8.5% decrease(74.7% decrease?53.7% increase). There was no significant difference in the both subjective and objective parameters at 6 months between the two groups; more and less than 500% increase on the 7th day, and among the three groups; more than 20% decrease(n=14), less than 20% decrease or increase(n=13), and more than 20% increase(n=13). However, improvement of MFR and AFR was significantly(p<0.05) higher at 6 months in 20% decrease group(n=9) compared with that of the remainder(n=17) although symptom scores and PVR not significantly different. CONCLUSIONS: Serum level of PSA at 7 days and 3 months after HE-TUMT could not predict efficacy of the treatment at 6 months. However, the extent of decrease in PSA level may represent relieved bladder outlet obstruction resulting from reduction of prostate volume.
